Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 214

Similar articles for PubMed (Select 21431343)

1.

High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer.

Endo Y, Toyama T, Takahashi S, Sugiura H, Yoshimoto N, Iwasa M, Kobayashi S, Fujii Y, Yamashita H.

Int J Clin Oncol. 2011 Oct;16(5):512-8. doi: 10.1007/s10147-011-0215-5. Epub 2011 Mar 23.

PMID:
21431343
2.

p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors.

Yamamoto M, Hosoda M, Nakano K, Jia S, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H.

Cancer Sci. 2014 Jan;105(1):81-8. doi: 10.1111/cas.12302. Epub 2013 Nov 22.

PMID:
24118529
3.

Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer.

Anderson H, Hills M, Zabaglo L, A'hern R, Leary AF, Haynes BP, Smith IE, Dowsett M.

Ann Oncol. 2011 Aug;22(8):1770-6. doi: 10.1093/annonc/mdq700. Epub 2011 Feb 1.

4.

Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.

Toi M, Saji S, Masuda N, Kuroi K, Sato N, Takei H, Yamamoto Y, Ohno S, Yamashita H, Hisamatsu K, Aogi K, Iwata H, Takada M, Ueno T, Saji S, Chanplakorn N, Suzuki T, Sasano H.

Cancer Sci. 2011 Apr;102(4):858-65. doi: 10.1111/j.1349-7006.2011.01867.x. Epub 2011 Feb 10.

PMID:
21231986
5.

Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.

Chanplakorn N, Chanplakorn P, Suzuki T, Ono K, Chan MS, Miki Y, Saji S, Ueno T, Toi M, Sasano H.

Breast Cancer Res Treat. 2010 Apr;120(3):639-48. doi: 10.1007/s10549-010-0785-3. Epub 2010 Feb 12.

PMID:
20151319
6.

Factors predictive of response to hormone therapy in breast cancer.

Rastelli F, Crispino S.

Tumori. 2008 May-Jun;94(3):370-83. Review.

7.

Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer.

Yamashita H, Takahashi S, Ito Y, Yamashita T, Ando Y, Toyama T, Sugiura H, Yoshimoto N, Kobayashi S, Fujii Y, Iwase H.

Cancer Sci. 2009 Nov;100(11):2028-33. doi: 10.1111/j.1349-7006.2009.01274.x. Epub 2009 Jul 6.

PMID:
19659610
8.

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS.

J Clin Oncol. 2009 Jun 1;27(16):2630-7. doi: 10.1200/JCO.2008.18.8391. Epub 2009 Apr 20.

9.

Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer.

Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, Coutant C, Rouzier R, Barranger E, Hortobagyi GN, Mauro D, Pusztai L.

Breast Cancer Res Treat. 2012 Sep;135(2):619-27. doi: 10.1007/s10549-012-2194-2. Epub 2012 Aug 14.

PMID:
22890751
10.

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.

J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8. doi: 10.1093/jnci/djn309. Epub 2008 Sep 23.

12.

Anti-tumor effects of letrozole.

Miller WR, Anderson TJ, Dixon JM.

Cancer Invest. 2002;20 Suppl 2:15-21. Review.

PMID:
12442345
13.

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M.

J Clin Oncol. 2009 Nov 20;27(33):5538-46. doi: 10.1200/JCO.2009.23.3734. Epub 2009 Sep 28.

14.

In situ aromatase expression in primary tumor is associated with estrogen receptor expression but is not predictive of response to endocrine therapy in advanced breast cancer.

Lykkesfeldt AE, Henriksen KL, Rasmussen BB, Sasano H, Evans DB, Møller S, Ejlertsen B, Mouridsen HT.

BMC Cancer. 2009 Jun 16;9:185. doi: 10.1186/1471-2407-9-185.

15.

18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.

Cheng J, Lei L, Xu J, Sun Y, Zhang Y, Wang X, Pan L, Shao Z, Zhang Y, Liu G.

J Nucl Med. 2013 Mar;54(3):333-40. doi: 10.2967/jnumed.112.111963. Epub 2013 Feb 11.

16.

Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer.

Torrisi R, Bagnardi V, Pruneri G, Ghisini R, Bottiglieri L, Magni E, Veronesi P, D'Alessandro C, Luini A, Dellapasqua S, Viale G, Goldhirsch A, Colleoni M.

Br J Cancer. 2007 Sep 17;97(6):802-8. Epub 2007 Aug 21.

17.

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR.

J Clin Oncol. 2005 Jan 20;23(3):619-29. Epub 2004 Nov 15. Review.

PMID:
15545664
18.

Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer.

Svahn TH, Niland JC, Carlson RW, Hughes ME, Ottesen RA, Theriault RL, Edge SB, Schott AF, Bookman MA, Weeks JC.

J Natl Compr Canc Netw. 2009 Feb;7(2):115-21.

PMID:
19200415
19.

Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.

Yamashita H, Yando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H.

Breast Cancer. 2006;13(1):74-83.

20.

[Neoadjuvant endocrine therapy for postmenopausal estrogen receptor-positive patients with breast cancer].

Zhang B.

Zhonghua Zhong Liu Za Zhi. 2011 Apr;33(4):241-4. Review. Chinese. No abstract available.

PMID:
21575491
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk